Literature DB >> 33416007

Association between Site-of-Care and the Cost and Modality of Radiotherapy for Prostate Cancer: Analysis of Medicare Beneficiaries from 2015 to 2017.

Kathryn R Tringale1, Renee L Gennarelli2, Erin F Gillespie1, Aaron P Mitchell2, Michael J Zelefsky1.   

Abstract

Among 84,447 radiotherapy (RT) courses for Medicare beneficiaries age ≥ 65 with prostate cancer treated with external beam RT (EBRT), brachytherapy, or both, 42,608 (51%) were delivered in hospital-affiliated and 41,695 (49%) in freestanding facilities. Freestanding centers were less likely to use EBRT + brachytherapy than EBRT (OR 0.84 [95%CI 0.84-0.84]; p < .001). Treatment was more costly in freestanding centers (mean difference $2,597 [95%CI $2,475-2,719]; p < .001). Adjusting for modality and fractionation, RT in hospital-affiliated centers was more costly (mean difference $773 [95%CI $693-853]; p < .001). Freestanding centers utilized more expensive RT delivery, but factors unrelated to RT modality or fractionation rendered RT more costly at hospital-affiliated centers.

Entities:  

Keywords:  Prostate cancer; episode-based payment; radiation oncology; site-neutrality

Mesh:

Year:  2021        PMID: 33416007      PMCID: PMC8285070          DOI: 10.1080/07357907.2020.1865396

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  29 in total

1.  Brachytherapy provides comparable outcomes and improved cost-effectiveness in the treatment of low/intermediate prostate cancer.

Authors:  Chirag Shah; Thomas B Lanni; Mihai I Ghilezan; Gary S Gustafson; Kimberly S Marvin; Hong Ye; Frank A Vicini; Alvaro A Martinez
Journal:  Brachytherapy       Date:  2012-06-23       Impact factor: 2.362

2.  Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer.

Authors:  W James Morris; Scott Tyldesley; Sree Rodda; Ross Halperin; Howard Pai; Michael McKenzie; Graeme Duncan; Gerard Morton; Jeremy Hamm; Nevin Murray
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-11-24       Impact factor: 7.038

3.  Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate.

Authors:  Jinka R Sathya; Ian R Davis; Jim A Julian; Qing Guo; Dean Daya; Ian S Dayes; Himu R Lukka; Mark Levine
Journal:  J Clin Oncol       Date:  2005-02-20       Impact factor: 44.544

4.  Brachytherapy for Patients With Prostate Cancer: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update.

Authors:  Joseph Chin; R Bryan Rumble; Marisa Kollmeier; Elisabeth Heath; Jason Efstathiou; Tanya Dorff; Barry Berman; Andrew Feifer; Arthur Jacques; D Andrew Loblaw
Journal:  J Clin Oncol       Date:  2017-03-27       Impact factor: 44.544

Review 5.  Recent Developments in Radiotherapy.

Authors:  Deborah E Citrin
Journal:  N Engl J Med       Date:  2017-09-14       Impact factor: 91.245

6.  Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO, and AUA Evidence-Based Guideline.

Authors:  Scott C Morgan; Karen Hoffman; D Andrew Loblaw; Mark K Buyyounouski; Caroline Patton; Daniel Barocas; Soren Bentzen; Michael Chang; Jason Efstathiou; Patrick Greany; Per Halvorsen; Bridget F Koontz; Colleen Lawton; C Marc Leyrer; Daniel Lin; Michael Ray; Howard Sandler
Journal:  Pract Radiat Oncol       Date:  2018-10-11

Review 7.  Defining Value in Radiation Oncology: Approaches to Weighing Benefits vs Costs.

Authors:  Andre A Konski
Journal:  Oncology (Williston Park)       Date:  2017-04-15       Impact factor: 2.990

8.  Consequences of physicians' ownership of health care facilities--joint ventures in radiation therapy.

Authors:  J M Mitchell; J H Sunshine
Journal:  N Engl J Med       Date:  1992-11-19       Impact factor: 91.245

9.  Total Medicare Costs Associated With Diagnosis and Treatment of Prostate Cancer in Elderly Men.

Authors:  Justin G Trogdon; Aaron D Falchook; Ramsankar Basak; William R Carpenter; Ronald C Chen
Journal:  JAMA Oncol       Date:  2019-01-01       Impact factor: 31.777

Review 10.  Cost effectiveness of prostate cancer radiotherapy.

Authors:  Andre Konski
Journal:  Transl Androl Urol       Date:  2018-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.